ClinicalTrials.gg
RecruitingNCT04278118HiPPIUpdated Feb 17, 2026

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

An interventional study of Hypofractionated Radiation Therapy and Photon Beam Radiation Therapy in Grade I Meningioma, Grade II Meningioma and Grade III Meningioma, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
25th of 107
70 · median 30
Started
2020
with 6 others
No phase
14 of 129
4 open now
Primary completion
2030-12
later than 34 of 37 live
Registered
99th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one is the 25th largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2020, is one of 14 with no phase, reaches primary completion later than 34 of the 37 other live ones, and was the 99th registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.

Read the detailed description

PRIMARY OBJECTIVE:

I. To report 3 year local tumor control of moderately hypofractionated proton or photon therapy for benign intracranial tumors.

SECONDARY OBJECTIVES:

I. To demonstrate feasibility of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors.

II. To report physician reported acute and late toxicity of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

III. To report neurocognitive effects, health related quality of life, and patient reported toxicity for moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT I: Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.

COHORT II: Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

03

Conditions studied

  • Grade I Meningioma
  • Grade II Meningioma
  • Grade III Meningioma
  • Intracranial Neoplasm
  • Nerve Sheath Neoplasm
  • Pituitary Gland Adenoma
  • Schwannoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed
  • Recommended to receive proton or photon fractionated radiation therapy
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Pregnant females are excluded. Female of (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.

    • A female of childbearing potential (FCBP) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally for at least 12 consecutive months (if age >= 55 years); if the female subject is \< 55 years and she has been naturally postmenopausal for >= 1 year her reproductive status has to be verified by additional laboratory (lab) tests (\< 20 estradiol OR estradiol \< 40 with follicle stimulating hormone [FSH] > 40 in women not on estrogen replacement therapy)
  • Prior radiation therapy that would overlap with current target volume
  • Inability to undergo magnetic resonance imaging (MRI)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Cohort I (hypofractionated radiation therapy)

    Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.

    Radiation: Hypofractionated Radiation Therapy · Radiation: Photon Beam Radiation Therapy · Radiation: Proton Beam Radiation Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Cohort II (hypofractionated radiation therapy)

    Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.

    Radiation: Hypofractionated Radiation Therapy · Radiation: Photon Beam Radiation Therapy · Radiation: Proton Beam Radiation Therapy · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • RadiationHypofractionated Radiation Therapy

    Undergo hypofractionated proton or photon radiation therapy

    Also known as: Hypofractionated Radiotherapy, hypofractionation

  • RadiationPhoton Beam Radiation Therapy

    Undergo hypofractionated proton or photon radiation therapy

  • RadiationProton Beam Radiation Therapy

    Undergo hypofractionated proton or photon radiation therapy

    Also known as: PBRT, Proton Radiation Therapy, Radiation, Proton Beam

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. local tumor control

    Will assess local tumor control rate. Local tumor control is defined as freedom from progressive disease (PD). Will be calculated as the proportion of patients who did not experience PD within 3-year follow up with 95% binomial proportion confidence interval for the entire population and each cohort independently. The same calculation will be repeated for the entire study population and each cohort separately. Kaplan-Meier method will be used to estimate the local control rates for the entire population and each cohort independently.

    Time frame: Up to 3 years since enrollment

  2. Incidence of adverse events

    Will be assessed and graded according to Common Terminology Criteria for Adverse Events version 5.0

    Time frame: up to 3 years

Secondary outcomes

  1. Neurocognitive effects

    Will be summarized by summary statistics.

    Time frame: Up to 3 years

  2. Health related quality of life

    Will be summarized by summary statistics.

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Dec 2030, 129 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2020
First posted
Feb 20, 2020
StartActual
Feb 18, 2020
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2031
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04278118
Lead sponsor
Emory University
Responsible party
Bree Eaton (Principal Investigator, Emory University) — Principal investigator
First posted
Feb 20, 2020
Start date
Feb 18, 2020
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Feb 17, 2026

Study contacts

Bree R Eaton
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion